There are no data on successfully treating hepatic and lung visceral crisis of a breast cancer with dual anti-HER2 monoclonal blockade combined with chemotherapy, and we anticipate that our experience in the future could become a frequent and common practice. This evidence concerns the gene ERBB2 and breast carcinoma.